Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,975
Closed -$246K 390
2025
Q1
$246K Sell
3,975
-38,901
-91% -$2.58M 0.03% 328
2024
Q4
$3.09M Buy
42,876
+1,361
+3% +$106K 0.33% 69
2024
Q3
$3.38M Buy
41,515
+52
+0.1% +$4.16K 0.44% 58
2024
Q2
$3.08M Buy
41,463
+941
+2% +$70.5K 0.41% 62
2024
Q1
$3.16M Buy
40,522
+698
+2% +$51.9K 0.43% 61
2023
Q4
$2.85M Sell
39,824
-21,739
-35% -$1.51M 0.44% 66
2023
Q3
$4.27M Buy
61,563
+1,116
+2% +$84.3K 0.65% 46
2023
Q2
$4.89M Sell
60,447
-408
-0.7% -$33.3K 0.72% 35
2023
Q1
$4.91M Buy
+60,855
New +$4.9M 0.77% 30

Other funds holding HOLX

Nilsine Partners's HOLX Position: Q2 2025 in Review

Nilsine Partners sold out of Hologic (HOLX) in Q2 2025, closing a stake of 3,975 shares — an estimated $246K sold.

Nilsine Partners first reported a position in HOLX in Q1 2023 and held it in 9 quarters. The position peaked at $4.91M in Q1 2023. 692 funds tracked by Wall St. Rank hold HOLX as of Q2 2025.

  • Nilsine Partners reported no remaining Hologic position as of Q2 2025 after selling out during the quarter.
  • Nilsine Partners sold 3,975 Hologic shares in Q2 2025, an estimated $246K.
  • Nilsine Partners first reported a position in Hologic in Q1 2023 and held it in 9 quarters.
  • Nilsine Partners's Hologic position peaked at $4.91M in Q1 2023.
  • 692 funds tracked by Wall St. Rank held Hologic as of Q2 2025.

Based on Nilsine Partners's 13F filing for Q2 2025, filed 31 Jul 2025.